Physician profile
Kuldev Singh
NPI 1093852253
$1,486,881.99
in general payments reported to CMS, 2019-2025
20 companies · $131K in 2025
The $131K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252K · 2020: $218K · 2021: $211K · 2022: $375K · 2023: $238K · 2024: $62K · 2025: $131K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $314K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111K · Food and Beverage: $4,367 · Travel and Lodging: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $314,374.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,937.00 |
| Food and Beverage | $4,367.06 |
| Travel and Lodging | $1,129.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $323,042.18 | 2022-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $312,005.57 | 2019-2023 | |
| Glaukos Corporation | $281,419.85 | 2019-2022 | |
| Alcon Vision LLC | $173,489.80 | 2019-2025 | Hydrus Microstent, Constellation, Clareon |
| Sight Sciences, INC. | $145,580.10 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Research LLC | $70,526.42 | 2019-2022 | |
| Ivantis, INC | $67,320.03 | 2019-2021 | |
| Allergan, INC. | $42,396.29 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $33,631.35 | 2023-2025 | Stellaris, Envista Envy Iol, Vyzulta |
| Ocular Therapeutix, INC. | $19,892.64 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $12,750.00 | 2025 | Product In Development |
| Johnson & Johnson Surgical Vision, INC. | $3,538.23 | 2019-2024 | Tecnis Iol, Tecnis Simplicity, Veritas Vision System |
| Abbvie INC. | $518.74 | 2023-2025 | Xen Glaucoma Treatment System |
| Janssen Research & Development, LLC | $285.00 | 2022 | |
| Thea Pharma INC. | $149.08 | 2025 | Iyuzeh |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $141.45 | 2022 | |
| Nova Eye, INC. | $65.58 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $54.94 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $37.69 | 2023 | Tecnis Simplicity |
| Oculus Surgical INC. | $37.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kuldev Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.